| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Agios Pharmaceuticals Inc (NASDAQ: AGIO)
AGIO Technical Analysis
4
| As on 9th Jun 2023 AGIO STOCK Price closed @ 25.87 and we RECOMMEND Sell for LONG-TERM with Stoploss of 27.16 & Strong Sell for SHORT-TERM with Stoploss of 31.62 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AGIOSTOCK Price
| Open | 26.71 | Change | Price | % |
| High | 26.71 | 1 Day | -0.73 | -2.74 |
| Low | 25.87 | 1 Week | 0.59 | 2.33 |
| Close | 25.87 | 1 Month | 3.55 | 15.91 |
| Volume | 223600 | 1 Year | -8.71 | -25.19 |
| 52 Week High 35.83 | 52 Week Low 17.06 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| AGIO Daily Charts |
AGIO Intraday Charts |
Whats New @ Bazaartrend |
AGIO Free Analysis |
|
|
AGIO Important Levels Intraday
| RESISTANCE | 27.49 |
| RESISTANCE | 26.97 |
| RESISTANCE | 26.65 |
| RESISTANCE | 26.33 |
| SUPPORT | 25.41 |
| SUPPORT | 25.09 |
| SUPPORT | 24.77 |
| SUPPORT | 24.25 |
AGIO Forecast May 2024
| 4th UP Forecast | 38.16 |
| 3rd UP Forecast | 34.22 |
| 2nd UP Forecast | 31.78 |
| 1st UP Forecast | 29.35 |
| 1st DOWN Forecast | 22.39 |
| 2nd DOWN Forecast | 19.96 |
| 3rd DOWN Forecast | 17.52 |
| 4th DOWN Forecast | 13.58 |
AGIO Weekly Forecast
| 4th UP Forecast | 31.63 |
| 3rd UP Forecast | 29.78 |
| 2nd UP Forecast | 28.64 |
| 1st UP Forecast | 27.50 |
| 1st DOWN Forecast | 24.24 |
| 2nd DOWN Forecast | 23.10 |
| 3rd DOWN Forecast | 21.96 |
| 4th DOWN Forecast | 20.11 |
AGIO Forecast2024
| 4th UP Forecast | 63.12 |
| 3rd UP Forecast | 51.17 |
| 2nd UP Forecast | 43.79 |
| 1st UP Forecast | 36.4 |
| 1st DOWN Forecast | 15.34 |
| 2nd DOWN Forecast | 7.95 |
| 3rd DOWN Forecast | 0.57 |
| 4th DOWN Forecast | -11.38 |
Agios Pharmaceuticals Inc ( NASDAQ USA Symbol : AGIO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AGIO Business Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts. Address: 88 Sidney Street, Cambridge, MA, United States, 02139-4169
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service